Accueil / Tag Archives: Oncology

Tag Archives: Oncology

Eleven Biotherapeutics to Present at Oppenheimer’s 27th Annual Healthcare Conference

Monday, March 20th 2017 at 12:00pm UTC CAMBRIDGE, Mass.–(BUSINESS WIRE)– Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), a late-stage clinical oncology company advancing a broad pipeline of novel product candidates based on its Targeting Protein Therapeutics (TPTs) platform, today announced that Stephen Hurly, President and Chief Executive Officer, will present a company overview …

Plus »

Chronix Biomedical Study Demonstrates Its Blood Test Can Predict Response to Cancer Immunotherapy

Monday, March 20th 2017 at 2:00pm UTC First study of a liquid biopsy to predict response to immunotherapy Highly accurate with a PPV of 92% and 100% for progression after one and two cycles respectively Early discovery of treatment-induced hyper-progressive disease Published in the peer-reviewed journal, Clinical Cancer Research SAN …

Plus »

Onxeo to Present Data Supporting Three Key Orphan Oncology Assets at AACR Annual Meeting

Tuesday, March 21st 2017 at 5:00pm UTC Preclinical studies of AsiDNATM, Livatag® and Beleodaq® PARIS–(BUSINESS WIRE)– class= »bwalignl »> Regulatory News: Onxeo S.A. (Paris:ONXEO) (NASDAQ OMX:ONXEO) (Euronext Paris, NASDAQ Copenhagen: ONXEO), a biotechnology company specializing in the development of innovative drugs for the treatment of orphan diseases, in particular in oncology, announced …

Plus »

ERYTECH présente de nouvelles données précliniques anti-tumorales avec erymethionase lors de l’AACR 2017

Monday, March 20th 2017 at 5:40pm UTC LYON, France–(BUSINESS WIRE)– Regulatory News: ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY), société biopharmaceutique de stade clinique développant à partir de sa plateforme propriétaire d’encapsulation de médicaments dans les globules rouges des thérapies innovantes contre des formes rares de cancers et des maladies orphelines, annonce aujourd’hui …

Plus »

Teewinot Life Sciences and Noramco Sign Letter of Intent to Produce Cannabinoids with Cannsynthesis™ Biocatalysis Technology

Monday, March 20th 2017 at 2:05pm UTC TAMPA, Fla. & WILMINGTON, Del.–(BUSINESS WIRE)– Teewinot Life Sciences (Teewinot), the market leader in biocatalytic technologies for the production of pharmaceutical-grade cannabinoids, and Noramco, a global leading producer of controlled-substance active pharmaceutical ingredients (APIs), today signed a letter of intent to enter the …

Plus »

Cerulean and Daré to Host Conference Call on Proposed Transaction on March 23

Tuesday, March 21st 2017 at 1:38am UTC CAMBRIDGE, Mass.–(BUSINESS WIRE)– Cerulean Pharma Inc. (NASDAQ:CERU), today announced jointly with Daré Bioscience that the companies will hold a joint conference call to discuss the definitive share purchase agreement under which the stockholders of Daré Bioscience will become the majority owners of Cerulean. …

Plus »

Cerulean Pharma and Daré Bioscience Enter into Stock Purchase Agreement

Monday, March 20th 2017 at 12:00pm UTC Transaction to create NASDAQ-listed company focused on the development and commercialization of women’s reproductive health products Sabrina Martucci Johnson to be Named CEO of Combined Company Cerulean and Daré to Host Joint Conference Call in March to Discuss Proposed Transaction and Dare’s Business …

Plus »

Novocure Receives MHLW Approval for Second Generation Optune® in Japan

Monday, March 20th 2017 at 11:00am UTC Second generation Optune is now approved in all active Novocure markets Optune is the first MHLW-approved therapy in more than a decade to demonstrate statistically and clinically significant extension of survival in newly diagnosed GBM patients ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ:NVCR) today …

Plus »

Syros Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Key Accomplishments and Upcoming Milestones

Monday, March 20th 2017 at 12:01pm UTC – Presented Data at Key Medical Meetings Further Supporting Therapeutic Potential of SY-1425 in Genomically Defined AML, MDS and Breast Cancer Patients – – Highlighted Data at Scientific Conferences Demonstrating Productivity of Syros’ Gene Control Platform in Oncology and Immuno-oncology – – On …

Plus »

Siamab Therapeutics to Present New Preclinical Data for Its Novel Antibodies and Antibody Drug Candidates at the American Association for Cancer Research Annual Meeting 2017

Tuesday, March 21st 2017 at 12:01pm UTC NEWTON, Mass.–(BUSINESS WIRE)– Siamab Therapeutics, Inc., a biopharmaceutical company developing novel cancer immunotherapies, today announced it will present preclinical data for its novel anti-Sialyl-Tn (STn) and anti-CD3 bispecific antibodies and antibody drug candidates (ADCs) during two poster presentations at the American Association for …

Plus »
Macbook Pro
* Intel Core i7 (3.8GHz, 6MB cache)
* Retina Display (2880 x 1880 px)
* NVIDIA GeForce GT 750M (Iris)
* 802.11ac Wi-Fi and Bluetooth 4.0
* Thunderbolt 2 (up to 20Gb/s)
* Faster All-Flash Storage (X1)
* Long Lasting Battery (9 hours)
BIENVENUE !
Vous appréciez cet article ? Faites-nous part de vos commentaires.
Recevez nos alertes, nos dernières actualités, suivez-nous, enregistrez-vous gratuitement, rejoignez notre communauté. Merci à vous !
ARE YOU READY? GET IT NOW!
Increase more than 500% of Email Subscribers!
Your Information will never be shared with any third party.
DÉCOUVREZ LA SOLUTION STRATA !
PGlmcmFtZSB3aWR0aD0iMTAwJSIgaGVpZ2h0PSIxMDAlIiBzcmM9Imh0dHA6Ly93d3cuZWVpLWJpb3RlY2hmaW5hbmNlcy5jb20vd3AtY29udGVudC91cGxvYWRzLzIwMTUvMDcvU2F0cmEtMi5tcDQiIGZyYW1lYm9yZGVyPSIwIiBhbGxvd2Z1bGxzY3JlZW4+PC9pZnJhbWU+
Retrouvez nous sur http://stratahealth.com/fr/
Un ensemble de solutions performantes
pour assurer le continuum de vos données.
SUIVEZ-NOUS, ENREGISTREZ-VOUS !
PGlmcmFtZSB3aWR0aD0iMTAwJSIgaGVpZ2h0PSIxMDAlIiBzcmM9Imh0dHA6Ly93d3cueW91dHViZS5jb20vZW1iZWQvajhsU2NITzJtTTAiIGZyYW1lYm9yZGVyPSIwIiBhbGxvd2Z1bGxzY3JlZW4+PC9pZnJhbWU+
All rights reserved © Company Name, 2014
Concours Genopole Young Biotech Award
* 100 000 € pour la meilleure Biotech
* Réservé aux biotechs hors santé
* 6 mois d'hébergement gratuit
* Un accompagnement personnalisé
* Etude de marché offerte
* Expertise du projet par EY
* Et nombre d'autres avantages...